专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09518112B2 TGF-β1 specific antibodies and methods and uses thereof 有权
标题翻译： TGF-β1特异性抗体及其方法和用途
公开(公告)号：US09518112B2
公开(公告)日：2016-12-13
申请号：US14383602
申请日：2013-03-06
申请人： Ludwig Institute for Cancer Research, LTD.
发明人： Jacques Van Snick , Catherine Uyttenhove , Thierry Boon
IPC分类号： C07K16/22 , A61K45/06 , G01N33/574 , A61K39/395 , A61K39/00
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/33 , C07K2317/565 , C07K2317/76 , G01N33/57488 , G01N2333/495 , G01N2800/52
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
摘要翻译：提供了与转化生长因子β1（TGF-β1）结合的特异性结合成员，特别是抗体及其片段，特别是识别人和小鼠TGF-β1，并且不识别或结合TGF-β2或TGF-β3。提供特异性识别和中和TGF-β1的特异性抗体。这些抗体可用于诊断和治疗与活化或升高的TGF-β1（包括癌症）和调节免疫细胞和免疫应答（包括对癌症或癌症抗原的免疫应答）相关的病症。抗TGF-β1抗体，其可变区或CDR结构域序列及其片段也可用于与化学治疗剂，免疫调节剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。这种抗体的例子有本发明的抗体，包括抗体13A1，其序列在此提供。

2. 发明授权

US11957751B2 TGF-β1 specific antibodies and methods and uses thereof 有权
公开(公告)号：US11957751B2
公开(公告)日：2024-04-16
申请号：US17174859
申请日：2021-02-12
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
发明人： Jacques Van Snick , Catherine Uyttenhove , Thierry Boon
IPC分类号： A61K39/395 , C07K16/22 , A61K39/00 , A61K45/06 , B65D51/20 , B65D51/22 , B65D55/02 , G01N33/574
CPC分类号： A61K39/3955 , C07K16/22 , A61K2039/505 , A61K45/06 , B65D51/20 , B65D51/22 , B65D55/026 , C07K2317/33 , C07K2317/565 , C07K2317/76 , G01N33/57488 , G01N2333/495 , G01N2800/52
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.

3. 发明授权

US10723793B2 TGF-β3 specific antibodies and methods and uses thereof 有权
公开(公告)号：US10723793B2
公开(公告)日：2020-07-28
申请号：US15580746
申请日：2016-06-10
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
发明人： Jacques Van Snick , Catherine Uyttenhove
IPC分类号： C07K16/22 , A61K47/68 , A61K39/395 , A61P35/04 , A61P35/00 , A61K45/06 , C07K16/30 , G01N33/574 , A61K39/00
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-β3) are provided, particularly recognizing human and mouse TGF-β3, particularly antibodies and fragments that do not recognize or bind TGF-β1 or TGF-β2. Particular antibodies are provided which specifically recognize and neutralize TGF-β3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody MTGF-β3-9, MTGF-β3-12, MTGF-β3-16, MTGF-β3-17 and MTGF-β3-19, whose sequences are provided herein.

4. 发明申请

US20150132319A1 TGF-BETA1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF 有权
标题翻译： TGF-β1特异性抗体及其用途及其用途
公开(公告)号：US20150132319A1
公开(公告)日：2015-05-14
申请号：US14383602
申请日：2013-03-06
申请人： Ludwig Institute for Cancer Research, LTD.
发明人： Jacques Van Snick , Catherine Uyttenhove , Thierry Boon
IPC分类号： C07K16/22 , A61K45/06 , G01N33/574 , A61K39/395
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/33 , C07K2317/565 , C07K2317/76 , G01N33/57488 , G01N2333/495 , G01N2800/52
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
摘要翻译：提供了与转化生长因子β1（TGF-β1）结合的特异性结合成员，特别是抗体及其片段，特别是识别人和小鼠TGF-β1，并且不识别或结合TGF-β2或TGF - ＆bgr; 3。提供特异性识别和中和TGF-β1的特异性抗体; 1。这些抗体可用于诊断和治疗与活化或升高的TGF-β1（包括癌症）和调节免疫细胞和免疫应答（包括对癌症或癌症抗原的免疫应答）相关的病症。抗TGF-β1抗体，其可变区或CDR结构域序列及其片段也可用于与化学治疗剂，免疫调节剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。这种抗体的例子有本发明的抗体，包括抗体13A1，其序列在此提供。

5. 发明授权

US11485780B2 TGF-β3 specific antibodies and methods and uses thereof 有权
公开(公告)号：US11485780B2
公开(公告)日：2022-11-01
申请号：US16913067
申请日：2020-06-26
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH, LTD.
发明人： Jacques Van Snick , Catherine Uyttenhove
IPC分类号： C07K16/22 , A61K47/68 , A61P35/00 , A61K39/395 , A61P35/04 , C07K16/30 , G01N33/574 , A61K45/06 , A61K39/00
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-β3) are provided, particularly recognizing human and mouse TGF-β3, particularly antibodies and fragments that do not recognize or bind TGF-β1 or TGF-β2. Particular antibodies are provided which specifically recognize and neutralize TGF-β3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody MTGF-β3-9, MTGF-β3-12, MTGF-β3-16, MTGF-β3-17 and MTGF-β3-19, whose sequences are provided herein.

6. 发明申请

US20210403545A1 TGF-B1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF 有权
公开(公告)号：US20210403545A1
公开(公告)日：2021-12-30
申请号：US17174859
申请日：2021-02-12
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
发明人： Jacques Van Snick , Catherine Uyttenhove , Thierry Boon
IPC分类号： C07K16/22 , A61K39/395
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.

7. 发明授权

US10947303B2 TGF-ß1 specific antibodies and methods and uses thereof 有权
公开(公告)号：US10947303B2
公开(公告)日：2021-03-16
申请号：US16046025
申请日：2018-07-26
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
发明人： Jacques Van Snick , Catherine Uyttenhove , Thierry Boon
IPC分类号： C07K16/22 , A61K39/395 , A61K45/06 , G01N33/574 , A61K39/00
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.

8. 发明申请

US20190092847A1 TGF-ß1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF 审中-公开
公开(公告)号：US20190092847A1
公开(公告)日：2019-03-28
申请号：US16046025
申请日：2018-07-26
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
发明人： Jacques Van Snick , Catherine Uyttenhove , Thierry Boon
IPC分类号： C07K16/22 , A61K45/06 , G01N33/574 , A61K39/395 , A61K39/00
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式